Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte-mediated Tumor Immunosurveillance: Abrogation Prevents Tumor Recurrence

Journal of Experimental Medicine

Volumn 198, Issue 11, 2003, Pages 1741-1752

  Terabe, Masaki ^a   Matsui, So ^a   Park, Jong Myun ^a   Mamura, Mizuko ^b   Noben Trauth, Nancy ^e   Donaldson, Debra D ^f   Chen, Wanjun ^c   Wahl, Sharon M ^c   Ledbetter, Steven ^g   Pratt, Bruce ^g   Letterio, John J ^b   Paul, William E ^d   Berzofsky, Jay A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^f PFIZER INC   (United States)

^g GENZYME CORPORATION   (United States)

Author keywords

IL 13; Immunologic surveillance; Myeloid cells; NKT cells; TGF

Indexed keywords

CD1D ANTIGEN; INTERLEUKIN 13; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 4 RECEPTOR ALPHA; RAG2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE ACTIVATION; IMMUNOSURVEILLANCE; KNOCKOUT MOUSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SPLEEN CELL; TIME SERIES ANALYSIS; TUMOR IMMUNOLOGY;

ANIMALS; ANTIGENS, CD1; BONE MARROW CELLS; CELL DIVISION; FEMALE; FLOW CYTOMETRY; IMMUNOPHENOTYPING; INTERLEUKIN-13; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; RECURRENCE; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 10744220561     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20022227     Document Type: Article

References (47)

1. Dunn, G.P., A.T. Bruce, H. Ikeda, L.J. Old, and R.D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3:991-998.
2. Khong, H.T., and N.P. Restifo. 2002. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3:999-1005.
3. Matsui, S., J.D. Ahlers, A.O. Vortmeyer, M. Terabe, T. Tsukui, D.P. Carbone, L.A. Liotta, and J. Berzofsky. 1999. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J. Immunol. 163:184-193.
4. Terabe, M., S. Matsui, N. Noben-Trauth, H. Chen, C. Watson, D.D. Donaldson, D.P. Carbone, W.E. Paul, and J.A. Berzofsky. 2000. NKT cell-mediated repression of tumour immunosurveillance by IL-13 and the IL-4R,-STAT6 pathway. Nat. Immunol. 1:515-520.
5. Ostrand-Rosenberg, S., M.J. Grusby, and V.K. Clements. 2000. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol. 165:6015-6019.
6. Kacha, A.K., F. Fallarino, M.A. Markiewicz, and T.F. Gajewski. 2000. Spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J. Immunol. 165:6024-6028.
7. Ostrand-Rosenberg, S., V.K. Clements, M. Terabe, J.M. Park, J. Berzofsky, and S.K. Dissanayake. 2002. Resistance to metastatic disease in Stat6-deficient mice requires hematopoietic and non-hematopoietic cells and is IFNγ-dependent. J. Immunol. 169:5796-5804.
8. Zurawski, G., and J.E. de Vries. 1994. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol. Today. 15:19-26.
9. Won, J., H. Kim, E.J. Park, Y. Hong, S.J. Kim, and Y. Yun. 1999. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy. Cancer Res. 59:1273-1277.
10. Arteaga, C.L., S.D. Hurd, A.R. Winnier, M.D. Johnson, B.M. Fendly, and J.T. Forbes. 1993. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J. Clin. Invest. 92:2569-2576.
11. Hoefer, M., and F.A. Anderer. 1995. Anti-(transforming growth factor beta) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice. Cancer Immunol. Immunother. 41:302-308.
12. Yang, Y.A., O. Dukhanina, B. Tang, M. Mamura, J.J. Letterio, J. MacGregor, S.C. Patel, S. Khozin, Z.Y. Liu, J. Green, et al. 2002. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109:1607-1615.
13. Muraoka, R.S., N. Dumont, C.A. Ritter, T.C. Dugger, D.M. Brantley, J. Chen, E. Easterly, L.R. Roebuck, S. Ryan, P.J. Gotwals, et al. 2002. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109:1551-1559.
14. Gorelik, L., and R.A. Flavell. 2001. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 7:1118-1122.
15. Donaldson, D.D., M.J. Whitters, L.J. Fitz, T.Y. Neben, H. Finnerty, S.L. Henderson, R.M. O'Hara, Jr., D.R. Beier, K.J. Turner, C.R. Wood, et al. 1998. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J. Immunol. 161:2317-2324.
16. Dasch, J.R., D.R. Pace, W. Waegell, D. Inenaga, L. Ellingsworth, and J.B. Allen. 1989. Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J. Immunol. 142:1536-1541.
17. Strockbine, N.A., L.R. Marques, R.K. Holmes, and A.D. O'Brien. 1985. Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect. Immun. 50:695-700.
18. Matsuda, J.L., O.V. Naidenko, L. Gapin, T. Nakayama, M. Taniguchi, C.R. Wang, Y. Koezuka, and M. Kronenberg. 2000. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192:741-753.
19. Kronenberg, M., and L. Gapin. 2002. The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. 2:557-568.
20. Mule, J.J., S.L. Schwarz, A.B. Roberts, M.B. Sporn, and S.A. Rosenberg. 1988. Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol. Immunother. 26:95-100.
21. Koblish, H.K., C.A. Hunter, M. Wysocka, G. Trinchieri, and W.M. Lee. 1998. Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. J. Exp. Med. 188:1603-1610.
22. Ahlers, J.D., I.M. Belyakov, M. Terabe, R. Koka, D.D. Donaldson, E. Thomas, and J.A. Berzofsky. 2002. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with GM-CSF and CD40L. Proc. Natl. Acad. Sci. USA. 99:13020-13025.
23. Kodera, T., T.L. McGaha, R. Phelps, W.E. Paul, and C.A. Bona. 2002. Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-beta production by fibroblasts. Proc. Natl. Acad. Sci. USA. 99:3800-3805.
24. Lagasse, E., and I.L. Weissman. 1996. Flow cytometric identification of murine neutrophils and monocytes. J. Immunol. Methods. 197:139-150.
25. Bronte, V., P. Serafini, E. Apolloni, and P. Zanovello. 2001. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J. Immunother. 24:431-446.
26. Bronte, V., M. Wang, W.W. Overwijk, D.R. Surman, F. Pericle, S.A. Rosenberg, and N.P. Restifo. 1998. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J. Immunol. 15:5313-5320.
27. Bronte, V., E. Apolloni, A. Cabrelle, R. Ronca, P. Serafini, P. Zamboni, N.P. Restifo, and P. Zanovello. 2000. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood. 96:3838-3846.
28. Salvadori, S., G. Martinelli, and K. Zier. 2000. Resection of solid tumors reverses T cell defects and restores protective immunity. J. Immunol. 164:2214-2220.
29. Kusmartsev, S.A., Y. Li, and S.H. Chen. 2000. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J. Immunol. 165:779-785.
30. Young, M.R., M.A. Wright, J.P. Matthews, I. Malik, and M. Prechel. 1996. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. J. Immunol. 156:1916-1922.
31. Cauley, L.S., E.E. Miller, M. Yen, and S.L. Swain. 2000. Superantigen-induced CD4 T cell tolerance mediated by myeloid cells and IFN-gamma. J. Immunol. 165:6056-6066.
32. Terabe, M., M. Shimizu, A. Mabuchi, S. Matui, H. Morikawa, K. Kaneda, T. Kakiuchi, and K. Yokomuro. 2000. Unresponsiveness of intrahepatic lymphocytes to bacterial superantigen: rapid development of suppressive Mac-1(high) cells in the mouse liver. Hepatology. 32:507-513.
33. Wahl, S.M., D.A. Hunt, G. Bansal, N. McCartney-Francis, L. Ellingsworth, and J.B. Allen. 1988. Bacterial cell wall-induced immunosuppression. Role of transforming growth factor beta. J. Exp. Med. 168:1403-1417.
34. Pelaez, B., J.A. Campillo, J.A. Lopez-Asenjo, and J.L. Subiza. 2001. Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. J. Immunol. 166:6608-6615.
35. Angulo, I., F.G. de las Heras, J.F. Garcia-Bustos, D. Gargallo, M.A. Munoz-Fernandez, and M. Fresno. 2000. Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood. 95:212-220.
36. Loke, P., A.S. MacDonald, and J.E. Allen. 2000. Antigen-presenting cells recruited by Brugia malayi induce Th2 differentiation of naive CD4(+) T cells. Eur. J. Immunol. 30:1127-1135.
37. Marshall, M.A., D. Jankovic, V.E. Maher, A. Sher, and J.A. Berzofsky. 2001. Mice infected with Schistosoma mansoni develop a novel non-T lymphocyte suppressor population which inhibits virus-specific CTL induction via a soluble factor. Microbes Infect. 3:1051-1061.
38. Schleifer, K.W., and J.M. Mansfield. 1993. Suppressor macrophages in African trypanosomiasis inhibit T cell proliferative responses by nitric oxide and prostaglandins. J. Immunol. 151:5492-5503.
39. al-Ramadi, B.K., M.A. Brodkin, D.M. Mosser, and T.K. Eisenstein. 1991. Immunosuppression induced by attenuated Salmonella. Evidence for mediation by macrophage precursors. J. Immunol. 146:2737-2746.
40. Kuwata, T., I.M. Wang, T. Tamura, R.M. Ponnamperuma, R. Levine, K.L. Holmes, H.C. Morse, L.M. De Luca, and K. Ozato. 2000. Vitamin A deficiency in mice causes a systemic expansion of myeloid cells. Blood. 95:3349-3356.
41. Schmielau, J., and O.J. Finn. 2001. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 61:4756-4760.
42. Young, M.R., M.A. Wright, Y. Lozano, J.P. Matthews, J. Benefield, and M.M. Prechel. 1996. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int. J. Cancer. 67:333-338.
43. Gumperz, J.E., C. Roy, A. Makowska, D. Lum, M. Sugita, T. Podrebarac, Y. Koezuka, S.A. Porcelli, S. Cardell, M.B. Brenner, et al. 2000. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity. 12:211-221.
44. Wu, D.Y., N.H. Segal, S. Sidobre, M. Kronenberg, and P.B. Chapman. 2003. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med. 198:173-181.
45. 1. J. Exp. Med. 194:809-822.
46. Chiaramonte, M.G., D.D. Donaldson, A.W. Cheever, and T.A. Wynn. 1999. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J. Clin. Invest. 104:777-785.
47. Czaja, M.J., F.R. Weiner, K.C. Flanders, M.A. Giambrone, R. Wind, L. Biempica, and M.A. Zern. 1989. In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. J. Cell Biol. 108:2477-2482.